Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric Subjects With Primary Immunodeficiency Diseases
Phase of Trial: Phase III
Latest Information Update: 22 Mar 2018
At a glance
- Drugs Immune globulin (Primary)
- Indications Immunodeficiency disorders
- Focus Therapeutic Use
- Sponsors Baxalta; Shire
- 23 Feb 2018 Planned End Date changed from 28 Nov 2021 to 14 Sep 2022.
- 23 Feb 2018 Planned primary completion date changed from 28 Nov 2021 to 14 Sep 2022.
- 25 Oct 2017 Status changed from not yet recruiting to recruiting.